In commercial plans and employer groups, adoption is accelerating: a 2025 Health Affairs/KFF survey found that 43% of firms with 5,000+ employees now cover GLP-1s for weight loss, up from 28% in 2024 ( [26] ), and 57% of employers overall cover GLP-1s for weight loss according to WTW survey data ( [27] )
Barriers to Access Beyond the Price Tag Even with falling prices, there are non-financial barriers that block fair access
It will be important for further research to study this topic as it relates specifically to treatment with GLP-1 medications
that, helps regulate, blood sugar and, digestion
We promise we will not spam or pester you
In contrast, at higher concentrations of 1.0 mM and 4.0 mM, the MSNs-ss-SA treatment resulted in 46.67% and 50.09% reduction in lesion length, respectively, compared with those of the control treatment